-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cold agglutinins (CAs) are autoantibodies, usually belonging to the IgM class, that directly target surface proteins expressed on red blood cells (rbc)
Cold agglutinins (CAs) are autoantibodies, usually belonging to the IgM class, that directly target surface proteins expressed on red blood cells (rbc)
After infection or trauma, a 100-1000-fold increase in complement activity will exacerbate hemolysis, and may lead to a significant drop in hemoglobin level.
A foreign research team described a white male who had a 10-year history of coronary heart disease (CHD), who was treated with three stents in the right coronary artery (RCA) for myocardial infarction
A foreign research team described a white male who had a 10-year history of coronary heart disease (CHD), with three right coronary artery (RCA) stents for myocardial infarction as a manifestation
Sutizumab is a complement c1 inhibitor that can selectively block classic complement activation, but retains the alternative and lectin pathways
Sutizumab is a complement c1 inhibitor that can selectively block classic complement activation, but retains the alternative and lectin pathways.
The patient was admitted to the hospital on day 0 for cardiac surgery and was given regular injections of sutizumab
The current case shows that even with obvious tissue trauma, acute phase response and simultaneous changes in volume status, sutizumab effectively prevents complement activation
The current case shows that even with obvious tissue trauma, acute-phase reactions, and simultaneous changes in volume status, sutizumab can effectively prevent complement activation.
Therefore, patients who are not taking sultizumab may require higher doses than those who do
Original source:
Tvedt, THA, Steien, E.
Tvedt, THA, Steien, E.
, Øvrebø, B.
, Haaverstad, R.
, Hobbs, W.
, Wardęcki, M.
, Tjønnfjord, GE and Berentsen, SA (2021), Sutimlimab, an investigational C1s inhibitor, effectively prevents exacerbation of hemolytic anaemia in a patient with cold agglutinin disease undergoing major surgery.
Am J Hematol.
Accepted Author Manuscript.
https://doi.
org/10.
1002/ajh.
26409
Leave a message here
